Alcoholic Hepatitis Therapeutics Market Size, Share, Global Trends, Forecast to 2028

Alcoholic Hepatitis Therapeutics Market

Alcoholic Hepatitis Therapeutics Market - By Product Type (Monoclonal Antibodies, Corticosteroids, Hemorheologic agents, Caspase protease inhibitor, Anabolic steroids, Sulfhydryl agents, and Hepatotropic Hormones), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), And By Region- Global Industry Perspective, Comprehensive Analysis, and Forecast, 2021 – 2028

Category: Healthcare Report Format : PDF Pages: 120 Report Code: ZMR-6600 Published Date: Aug-2021 Status : Published
Market Size in 2020 Market Forecast in 2028 CAGR (in %) Base Year
USD 673 Million USD 1,013 Million 6.1% 2020

Alcoholic Hepatitis Therapeutics Market

Global Alcoholic Hepatitis Therapeutics Market: Industry Perspective

The global Alcoholic Hepatitis Therapeutics Market accrued earnings worth approximately 673 USD Million in 2020 and is predicted to gain revenue of about 1,013 USD Million by 2028, is set to record a CAGR of nearly 6.1% over the period from 2021 to 2028. The report offers assessment and analysis of the alcoholic hepatitis therapeutics market on a global and regional level. The study offers a comprehensive assessment of the market competition, constraints, revenue estimates, opportunities, evolving trends, and industry-validated data. The report provides historical data from 2018 to 2020 along with a forecast from 2021 to 2028 based on revenue USD Million.

Global Alcoholic Hepatitis Therapeutics Market SizeRequest Free Sample

Alcoholic Hepatitis Therapeutics Market: Synopsis

Alcoholic hepatitis is severe hepatic inflammation related to morbidity & mortality and occurs in persons consuming large proportion of alcohol. In addition to this, it is a syndrome in patients that causes acute chronic liver failure. Apparently, alterations in gut microbiota, cytokine signaling & inflammation, mitochondrial dysfunction, oxidative stress, and abnormities in hepatic regeneration capacity are predicted to contribute towards alcoholic hepatitis pathology.

Furthermore, hospitalized alcoholic hepatitis patients result in massive healthcare expenditure and hence it is necessary for finding an effective treatment for this ailment. Additionally, alcoholic hepatitis can affect the gastrointestinal system, hematologic system, renal system, central nervous system, and cardiovascular system. It can injure hepatocyte and impair intestinal barrier activity. Symptoms of the alcoholic hepatitis include anorexia, fever, fatigue, weight loss, and right upper quadrant abdominal pain.

In addition to this, alcoholic hepatitis is a multisystem ailment that occurs due to intake of alcohol in huge quantities over an elongated period. Growth of the disease depends on ecological & genetic aspects. The key treatment for the disease includes abstinence from alcohol beverage consumption & supportive patient care. Moreover, corticosteroids are the most efficient medical treatment method but they can only improve the rate of survival in selective groups of patients for only a shorter period. 

Reportedly, men consuming over 100 gram of ethanol regularly for more than five years are at high risk of getting affected from alcoholic hepatitis. While in the case of women, ingesting a small proportion of ethanol in short term can cause alcoholic hepatitis. Some of other treatments for alcoholic hepatitis include nutritious food and use of medicines such as methadone, pentoxifylline, and N-acetyl cysteine. Additionally, behavioral therapy, baclofen, and rehabilitation are some of the other therapies that are utilized in treating alcoholic hepatitis.  Other emerging treatments include probiotics, antibiotics, zinc, melatonin, FXR agonist, mycophenolate, emricasan, anakinra, mitoq, metadoxine, interleukin-22, and erythropoietin.

Alcoholic Hepatitis Therapeutics Market: Growth Factors

The surge in intake of alcohol and a rise in alcoholic liver ailment will drive the growth of the alcoholic hepatitis therapeutics market. In addition to this, surging knowledge about the pathophysiology of alcoholic hepatitis along with the availability of substitute therapies will drive industry trends. For the record, nearly 56,809 hospital admissions with primary diagnosis of alcoholic hepatitis contributed nearly 0.71% of overall hospital admissions in the U.S. during 2007. Moreover, total hospitalization costs incurred on treating alcoholic hepatitis were more compared to costs incurred for treatment of acute cerebrovascular ailment, acute myocardial infarction, and acute pancreatitis. This, in turn, will drive growth of alcoholic hepatitis therapeutics market size.

Furthermore, a strong medicine pipeline is predicted to steer the expansion of the alcoholic hepatitis therapeutics market. In addition to this, rise in acceptance of new therapeutic medicines and increase in cases of liver transplantations in patients will further boost business trends.

Alcoholic Hepatitis Therapeutics Market: Regional Landscape

North American Market To Record Exponential Growth During 2021-2028

Prominent market expansion in North America over forecast period can be attributed to robust healthcare sector and adoption of new drugs for treating alcoholic hepatitis. In addition to this, the huge occurrence of disease in the region will further contribute to alcoholic hepatitis therapeutics' market value in North America over the upcoming years. In addition to this, the presence of major drug producers for treating the disease in the sub-continent will steer regional market growth.

Alcoholic Hepatitis Therapeutics Market: Report Scope

Report Attributes Report Details
Report Name Alcoholic Hepatitis Therapeutics Market Research Report
Market Size in 2020 USD 673 Million
Market Forecast in 2028 USD 1,013 Million
Growth Rate CAGR of 6.1%
Number of Pages 120
Key Companies Covered Sanofi, Gilead Sciences, Inc., Immuron Limited, Generon Pharmaceutical Technology Company Limited, and Intercept Pharmaceuticals, Ltd.
Segments Covered By Product Type, By Distribution Channel, And By Region
Regions Covered North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA)
Base Year 2020
Historical Year 2016 to 2020
Forecast Year 2021 - 2028
Customization Scope Avail customized purchase options to meet your exact research needs. Request For Customization

Alcoholic Hepatitis Therapeutics Market: Competitive Landscape

Some of the leading in the global market include

  • Sanofi
  • Gilead Sciences Inc.
  • Immuron Limited
  • Generon Pharmaceutical Technology Company Limited
  • Intercept Pharmaceuticals Ltd.

The global Alcoholic Hepatitis Therapeutics Market is segmented as follows:

By Product Type

By Distribution Channel

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table Of Content

Methodology

FrequentlyAsked Questions

Surge in intake of alcohol and rise in alcoholic liver ailment will drive growth of alcoholic hepatitis therapeutic market. In addition to this, surging knowledge about pathophysiology of alcoholic hepatitis along with availability of substitute therapies will drive business trends. For the record, nearly 56,809 hospital admissions with primary diagnosis of alcoholic hepatitis contributed nearly 0.71% of overall hospital admissions in the U.S. during 2007. Moreover, total hospitalization costs incurred on treating alcoholic hepatitis was more as compared to costs incurred on treatment of acute cerebrovascular ailment, acute myocardial infarction, and acute pancreatitis. This, in turn, will drive growth of alcoholic hepatitis therapeutics market size.

Furthermore, strong medicine pipeline is predicted to spur expansion of alcoholic hepatitis therapeutics market. In addition to this, rise in acceptance of new therapeutic medicines and increase in cases of liver transplantations in patients will further promulgate industry growth.

According to Zion market research report, the global Alcoholic Hepatitis Therapeutics market accrued earnings worth approximately 673 (USD Million) in 2020 and is predicted to gain revenue of about 1,013(USD Million) by 2028, is set to record a CAGR of nearly 6.1% over the period from 2021 to 2028.

North America will contribute lucratively towards the global market value over the estimated timeline. The regional market surge is subject to robust healthcare sector and acceptance of new drugs for treating alcoholic hepatitis. In addition to this, huge occurrence of disease in the region will further contribute towards alcoholic hepatitis therapeutics market value in North America over ensuing years. In addition to this, presence of major drug producers for treating the disease in the sub-continent will embellish regional market growth.

The key market participants include Sanofi, Gilead Sciences, Inc., Immuron Limited, Generon Pharmaceutical Technology Company Limited, and Intercept Pharmaceuticals, Ltd.

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed